This article is more than 5 years old. Information may no longer be current.

HPV16, HPV18 caused most invasive cervical cancers in New Mexico: 1980-1999

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Despite the fact that the majority of invasive cervical cancer cases identified in New Mexico during the last 20 years were caused by HPV16 and HPV18, the proportion of these cancers attributable to HPV16 has declined, according to data from the state’s SEER database.

Researchers identified 1,213 cases of in situ cervical cancer diagnosed between 1985 and 1999 and 808 cases of invasive cervical cancer diagnosed between 1980 and 1999. They performed HPV genotyping and estimated relative risks for cervical cancer.

HPV16 (53.2%), HPV18 (13.1%) and HPV45 (6.1%) were the most common HPV genotypes detected in invasive cancers. HPV16 (56.3%), HPV31 (12.6%) and HPV33 (8.0%) were most common detected in in situ cancers.

Participants positive for HPV16 (P=.0029) or HPV18 (P=.0013) were diagnosed with invasive cancer at younger ages compared with participants positive for carcinogenic HPV genotypes other than HPV16 or 18.

According to the researchers, the amount of HPV16-positive in situ and invasive cancers declined with more recent calendar year of diagnosis; however, the proportion of cases positive for carcinogenic HPV genotypes other than HPV18 increased.

“The authors spend much of their discussion using these data, as well as information from a number of other studies, to argue that the age for initiation of cervical cancer screening can be shifted to older ages in HPV-vaccinated populations,” Lauri E. Markowitz, MD, division of STD prevention, CDC, Elizabeth R. Unger, MD, HPV/pathology, CDC and Mona Saraiya, MD, MPH, medical officer, division of cancer prevention and control, National Center for Chronic Disease Prevention and Health Promotion, wrote in an accompanying editorial.

“The National Immunization Teen Survey conducted in 2007 found that 25% of females aged 13 to 18 years had received at least one dose of HPV vaccine. Vaccine coverage will likely increase in the United States, but it may be years before a highly vaccinated cohort reaches cervical cancer screening age. Lower vaccine coverage among some age cohorts or subgroups may complicate cervical cancer screening if recommendations for screening are based on vaccination history,” they wrote.

Wheeler CM. J Natl Cancer Inst. 2009;101:475-487.